Polymers Enhancing Bioavailability in Drug Delivery
This Special Issue provides an update on the state of the art and current trends in polymeric drug-delivery systems specifically designed for improving drug bioavailability. The multiple contributions received further strengthen the role of polymers in modern drug delivery and targeting, illustratin...
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_94506 | ||
| 005 | 20221206 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20221206s2022 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-5683-3 | ||
| 020 | |a 9783036556840 | ||
| 020 | |a 9783036556833 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-5683-3 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 072 | 7 | |a KNDP |2 bicssc | |
| 100 | 1 | |a Fernandes, Ana Isabel |4 edt | |
| 700 | 1 | |a Jozala, Angela |4 edt | |
| 700 | 1 | |a Fernandes, Ana Isabel |4 oth | |
| 700 | 1 | |a Jozala, Angela |4 oth | |
| 245 | 1 | 0 | |a Polymers Enhancing Bioavailability in Drug Delivery |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
| 300 | |a 1 electronic resource (260 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a This Special Issue provides an update on the state of the art and current trends in polymeric drug-delivery systems specifically designed for improving drug bioavailability. The multiple contributions received further strengthen the role of polymers in modern drug delivery and targeting, illustrating the different approaches possible and unveiling what the future may bring. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 650 | 7 | |a Pharmaceutical industries |2 bicssc | |
| 653 | |a cystic fibrosis | ||
| 653 | |a Pseudomonas aeruginosa | ||
| 653 | |a liposomes | ||
| 653 | |a efflux pump inhibitor | ||
| 653 | |a PABN | ||
| 653 | |a aminoglycosides | ||
| 653 | |a macrolides | ||
| 653 | |a poloxamer | ||
| 653 | |a thiourea | ||
| 653 | |a thiolation | ||
| 653 | |a mucoadhesion | ||
| 653 | |a drug release | ||
| 653 | |a in vivo analysis | ||
| 653 | |a in vitro dissolution studies | ||
| 653 | |a S-propargyl-cysteine | ||
| 653 | |a poly(lactic acid) | ||
| 653 | |a endogenous hydrogen sulfide | ||
| 653 | |a water-in-oil-in-water | ||
| 653 | |a rheumatoid arthritis | ||
| 653 | |a chitosan | ||
| 653 | |a drug delivery | ||
| 653 | |a drug absorption | ||
| 653 | |a intestinal assimilation | ||
| 653 | |a oral bioavailability | ||
| 653 | |a nanoemulsions | ||
| 653 | |a micelles | ||
| 653 | |a SEDDS | ||
| 653 | |a zeta potential | ||
| 653 | |a sustained release | ||
| 653 | |a albumin nanoparticle | ||
| 653 | |a MPT0B291 | ||
| 653 | |a high-pressure homogenizer | ||
| 653 | |a histone deacetylase | ||
| 653 | |a calix[8]arenes | ||
| 653 | |a silibinin | ||
| 653 | |a inclusion complexes | ||
| 653 | |a PEGylation | ||
| 653 | |a cytotoxicity | ||
| 653 | |a oromucosal films | ||
| 653 | |a sodium alginate | ||
| 653 | |a nanoparticle drug carriers | ||
| 653 | |a digoxin | ||
| 653 | |a zein | ||
| 653 | |a heart failure | ||
| 653 | |a polymer-liposome complexes | ||
| 653 | |a Pluronic®-poly(acrylic acid) | ||
| 653 | |a Pluronic®-poly(N,N-dimethylaminoethyl methacrylate) | ||
| 653 | |a stimuli-responsive | ||
| 653 | |a intelligent drug delivery systems | ||
| 653 | |a liposome | ||
| 653 | |a polymer | ||
| 653 | |a long circulation | ||
| 653 | |a polymer-lipid conjugates | ||
| 653 | |a targeting | ||
| 653 | |a stimulus-responsive | ||
| 653 | |a antibody | ||
| 653 | |a affinity | ||
| 653 | |a cyclodextrin | ||
| 653 | |a protein therapeutics | ||
| 653 | |a sustained drug delivery | ||
| 653 | |a Nitric oxide | ||
| 653 | |a hydrogel | ||
| 653 | |a wound dressing | ||
| 653 | |a chronic wounds | ||
| 653 | |a glycyrrhetinic acid | ||
| 653 | |a Soluplus® | ||
| 653 | |a solid dispersions | ||
| 653 | |a anti-inflammatory | ||
| 653 | |a biosafety | ||
| 653 | |a bioavailability | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/6330 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/94506 |7 0 |z DOAB: description of the publication |